Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Methods Mol Biol. 2024;2843:219-237. doi: 10.1007/978-1-0716-4055-5_14.
Essentially all bacteria secrete nano-sized (~20-200 nm) bacterial extracellular vesicles (bEVs) loaded with proteins, lipids, glycans, and nucleic acids. bEVs facilitate interactions among cells of the same species, different microbial species, and even with cells of multicellular organisms in the context of colonization or infection. Their interactions with host organism immune cell receptors vary depending on the producing bacterial species and are now being harnessed for the development of bEVs as a potential immunotherapeutic platform. Both basic/mechanistic and preclinical therapeutic development studies are thus increasing in number and require implementation of methods for multiparametric analytical characterization as well as in vivo administration in preclinical animal models of disease. We summarize a variety of analytical methods that can be used to calculate bEV dose for preparations made from diverse bacterial sources (including sterility testing, total protein concentration, particle concentration, and lipopolysaccharide concentration). We also describe basic methodology for intravenous administration of bEV preparations via tail vein injection in laboratory mice. Throughout the description of methodology, we highlight potential pitfalls and alternatives to further equip the reader for troubleshooting should challenges arise. Robust and reproducible characterization is a prerequisite of bEV preparation quality control and consistent dosing during preclinical development. This will allow for more streamlined testing of candidate therapeutic bEVs within a given research laboratory, and furthermore facilitate reproducibility of findings across laboratories.
基本上所有细菌都会分泌纳米级 (~20-200nm) 的细菌细胞外囊泡 (bEVs),其中装载有蛋白质、脂类、糖和核酸。bEVs 促进同种细菌细胞、不同微生物物种之间甚至与多细胞生物的细胞之间的相互作用,在定植或感染的情况下尤其如此。它们与宿主生物体免疫细胞受体的相互作用因产生细菌的种类而异,目前正在利用 bEVs 作为潜在的免疫治疗平台。因此,基础/机制和临床前治疗开发研究的数量都在增加,需要实施多参数分析特性描述方法以及在疾病的临床前动物模型中进行体内给药。我们总结了各种分析方法,可用于计算来自不同细菌源的 bEV 制剂的剂量(包括无菌测试、总蛋白浓度、颗粒浓度和脂多糖浓度)。我们还描述了通过尾静脉注射在实验室小鼠中静脉内给予 bEV 制剂的基本方法。在描述方法的过程中,我们强调了可能出现的问题和替代方法,以便在出现问题时为读者提供故障排除的方法。稳健且可重复的特性描述是 bEV 制剂质量控制和临床前开发过程中一致给药的前提。这将允许在给定的研究实验室中更精简地测试候选治疗性 bEVs,并且还可以促进实验室之间研究结果的可重复性。